Abstract: This disclosure concerns the systems, methods, and kits for the in vitro synthesis of biological macromolecules in a reaction utilizing cell lysates containing plastids, mitochondria and/or chloroplasts, wherein creatine phosphate and creatine kinase are not added to the reaction to provide artificial energy regeneration.

Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease.

Abstract: Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided.

Abstract: Disclosed are biodegradable insulation materials comprising a structural scaffold; and at least one temperature resilient fungus. Also disclosed are methods of making and using biodegradable insulation materials comprising a structural scaffold; and at least one temperature resilient fungus. For example, disclosed are methods of insulating an infrastructure comprising administering the disclosed biodegradable insulation materials to an infrastructure.

Abstract: Disclosed herein is a 3D-printed, biocompatible macroporous device that houses stem cell derived ?-cell (SC-? cell) clusters within a degradable fibrin gel. Cluster sizes are used that avoid severe hypoxia within 3D-printed devices and a microwell-based technique is used for resizing clusters within this range. 3D-printed devices may function for at least 12 weeks, are retrievable, and maintain structural integrity.

Abstract: This disclosure relates to the technical field of liver transplantation and discloses a set of biomarkers that can be used to assess the quality of the liver graft before transplantation. More specifically, this disclosure describes a process of predicting the appearance of primary non function (PNF) of a liver graft via determining the relative abundance of the undergalactosylated glycans in the perfusate N-glycome of the liver before transplantation.

Abstract: To provide an autoserum-containing bone marrow cell culture system, whereby bone marrow cells, which are collected from a subject without using an anticoagulant, are subjected to an anticoagulation treatment using a medium in a liquid-tight state, cultured and then further cultured using the serum of said subject which is prepared in a liquid-tight state; an autoserum-containing bone marrow cell culture method; and a method for producing a medicinal composition which comprises, as the active ingredient, autoserum-containing cultured bone marrow cells. [Solution] An autoserum-containing bone marrow cell culture system for culturing bone marrow cells, which are collected from a subject without using an anticoagulant, using the serum of said subject, said system comprising a bone marrow cell suspension-storing device, a collected blood-storing device, an autoserum-acquiring device, and a bone marrow cell-culturing device.

Abstract: Embodiments provide swallowable devices, preparations and methods for delivering viable cells (VC) into the GI tract including GI wall tissue or other tissue site. Particular embodiments provide a swallowable device such as a capsule for delivering VC into an intestinal wall or other site. The VC can be contained within a tissue-penetrating shell disposed in the capsule that protects the VC as they pass through the GI tract until they are inserted into GI tract tissue or other location. The shell desirably has shape, size and material consistency to be contained in a swallowable capsule, delivered from the capsule into solid tissue by the application of force on the shell and biodegrade within the solid tissue to release the VC into the tissue. Within the shell or other structure the VC can be maintained in a viability-sustaining gel that preserves the viability of the VC for selected time periods.

Abstract: The present invention provides a method for determining whether or not a test sample contains an Exserohilum phytopathogenic fungus. The method comprises: (a) putting the test sample on a front surface of a cellulose film having no through hole; (b) leaving the test sample at rest for a predetermined time; (c) observing a back surface of the cellulose film; and (d) determining that the test sample contains the Exserohilum phytopathogenic fungus, if a fungus which has penetrated the cellulose film is found on the back surface of the cellulose film in the step (c). The method further comprises a step of supplying a culture medium to the test sample before the step (b). The culture medium is a lactose casein hydrolysate agar medium containing carbendazim, captan, streptomycin sulfate, and neomycin sulfate. Alternatively, in the step (b), the test sample is left at rest while the back surface of the cellulose film is in contact with the culture medium.

Abstract: The invention generally relates to methods for quantifying an amount of enzyme molecules. Systems and methods of the invention are provided for measuring an amount of target by forming a plurality of fluid partitions, a subset of which include the target, performing an enzyme-catalyzed reaction in the subset, and detecting the number of partitions in the subset. The amount of target can be determined based on the detected number.

Abstract: The present invention provides a method for determining whether or not a test sample contains at least one phytopathogenic fungus selected from the group consisting of Gibberella fujikuroi, Fusarium avenaceum, and Glomerella tucumanensis. The method according to the present invention comprises: (a) putting the test sample on a front surface of a cellulose film; wherein the cellulose film has a thickness of not less than 0.5 micrometers and not more than 3.7 micrometers; (b) leaving the test sample at rest for not less than 4 hours and not more than 8 hours after the step (a); (c) observing a back surface of the film after the step (b); and (d) determining that the test sample contains at least one phytopathogenic fungus selected from the group consisting of Gibberella fujikuroi, Fusarium avenaceum, and Glomerella tucumanensis, if a fungus is found on the back surface of the film in the step (c).

Abstract: A hand dishwashing cleaning composition comprising a surfactant system including an anionic surfactant and an amine oxide co-surfactant wherein the weight ratio of the surfactant system to the amine oxide is from about 1.5:1 to about 4.5:1 and wherein the composition further includes a protease and an enzyme stabilizer selected from the group consisting of: potassium salts of halides, sulfates, sulfites, carbonates, hydrogencarbonates, nitrates, nitrites, phosphates, formates, acetates, propionates, citrates, maleates, tartarates, succinates, oxalates and lactates; a peptide aldehyde, peptide ketone, a hydrosulfite adduct thereof; a phenyl boronic acid, a derivative thereof and mixtures thereof.

Abstract: A Disease Severity Index (DSI) is provided for assessment of chronic liver disease in a patient using non-invasive liver function test results. A DSI was derived from non-invasive liver function test results based on hepatic blood flow. The DSI is used in methods for prediction of clinical outcomes, prediction of response to antiviral treatment, and assessment of progression of chronic liver diseases. Non-invasive methods to diagnose three distinct categories of patients with Primary Sclerosing Cholangitis (PSC) are provided. The methods can be used to diagnose PSC patients as Slow Progressors, Moderate Progressors and Rapid Progressors.

Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Abstract: A process for producing a transportation fuel from a lignocellulosic feedstock comprising subjecting a stream comprising lignin to a wet oxidation that produces low molecular weight carboxylic acids. These carboxylic acids and/or the corresponding esters are fed to a hydrogenation reaction or gas fermentation wherein they are converted to an alcohol. Heat from the wet oxidation may be supplied to any stage of the process in which heat is introduced.

Abstract: The present invention relates, in part, to methods and kits for rapidly determining antimicrobial susceptibility of microorganisms.

Abstract: The present invention discloses a microcapsule material capable of reducing pollution containing polycyclic aromatic hydrocarbons, and a preparation method and application thereof. The preparation method comprises the following steps: (1) culturing mycobacterium gilvum CP 13 in a bacteria culture liquid to obtain a bacterial broth, wherein the mycobacterium gilvum CP 13 was deposited in China General Microbiological Culture Collection Center (CGMCC) on Jul. 22, 2013 with a CGMCC number of CGMCC No. 7963; and (2) applying a calcium alginate and chitosan to encapsulate the bacterial broth in a microcapsule through layer-by-layer self-assembly to produce a microcapsule material capable of reducing pollution containing polycyclic aromatic hydrocarbons. The present invention produces a microcapsule material with the microorganic activity through layer-by-layer self-assembly, which has superior adaptability to the environment and good ability to reduce pollution containing polycyclic aromatic hydrocarbons.

Abstract: An object of the present invention is to provide high-quality 1,4BG capable of working out to a raw material of PBT with good color tone, by efficiently removing and refining impurities mixed when producing a biomass-derived 1,4BG on an industrial scale and the present invention relates to a production method of refined 1,4BG, where a crude 1,4BG-containing solution is obtained from refined raw material 1,4BG obtained by removing bacterial cells, salt contents and water from the fermentation culture medium, through a step of removing high-boiling-point components and/or low-boiling-point components by distillation and/or a step of converting an unsaturated compound to a hydride and the target product is obtained as a side stream in a further distillation step.

Abstract: A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, RNA. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or biotransformed products formed in situ. The bile salt export transport and/or formation activity modulation includes but not limited to inhibition, induction, activation and/or regulation. The method can be practiced to identify test agents, which have potential to cause liver injury, drug-drug interactions, and/or can be used as therapeutic agents for the treatment of cholestasis, abnormality of bile salt metabolism, liver diseases and cholesterol abnormality.

Abstract: Disclosed herein are methods and compositions for determining the presence or absence of a mechanism of antimicrobial resistance in a sample.